The Latest Breaking News from FDA

Argenx Targets FDA Label Expansion After Vyvgart Trial Success

Argenx SE (NASDAQ:ARGX) released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab).

Benzinga · Aug 25, 2025

Congress sees bipartisan bright spot in sunscreen legislation - Roll Call

Lawmakers are working on legislation to lower market barriers for new sunscreens, an effort to bring the U.S. in line with other countries.

Roll Call · Aug 25, 2025

11 Items Retailers Remove Before FDA Inspectors Arrive

Grocery store inspections are a routine part of keeping our food supply safe. When the FDA shows up, retailers want to present their best face and avoid costly violations. That’s why some items quietly disappear from shelves before inspectors walk in. Understanding what gets pulled can help shoppers make informed…

Grocery Coupon Guide · Aug 24, 2025

NBCUniversal, Netflix, ESPN Vie For Baseball Rights As Major League Baseball Seeks Bigger Revenues

Major League Baseball is in advanced talks with multiple media giants, including Comcast Corporation's (NASDAQ:CMCSA) NBCUniversal, Netflix Inc (NASDAQ:NFLX), and The Walt Disney Company's (NYSE:DIS) ESPN, on a series of new rights deals that could reshape how fans watch the sport.

Benzinga · Aug 22, 2025

Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting

Biohaven Ltd. (NYSE:BHVN) stock is trading higher on Friday following an update with respect to its New Drug Application for troriluzole for adult patients with Spinocerebellar Ataxia (SCA).

Benzinga · Aug 22, 2025

Worried About a Market Crash? Here Are 3 Stocks That ‘Big Short’ Star Michael Burry Loves Here.

Here are three top stocks that the ‘Big Short’ star Michael Burry owns in Q2 of 2025. Are UNH, REGN, and LULU undervalued right now?

Barchart · Aug 21, 2025

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Benzinga · Aug 21, 2025

Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a potential first new smoking cessation therapy in nearly two decades, positioning the company for a high-stakes commercial launch in 2026.

Benzinga · Aug 21, 2025

Why So Many Nutrition Panels Have Been Quietly Altered

If you have a keen eye, you may have noticed that the Nutrition Facts panel on your favorite packaged foods looks different from what it did a few years ago. These changes are not your imagination. Food manufacturers have been quietly altering their nutrition labels for a variety of reasons,…

Grocery Coupon Guide · Aug 21, 2025

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy

As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding capabilities and integrating advanced therapeutic platforms. Kite Pharma, a Gilead Sciences Inc. company (NASDAQ:GILD) on Thursday agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR…

Benzinga · Aug 21, 2025